Dirucotide trials for secondary progressive MS discontinued for lack of efficacy
Lilly and BioMS Medical reported that their investigational agent dirucotide did not meet the primary end point of delaying disease progression in patients with secondary progressive multiple sclerosis (SPMS) in the phase 3 MAESTRO-01 trial.
Lilly and BioMS Medical reported that their investigational agent dirucotide did not meet the primary end point of delaying disease progression in patients with secondary progressive multiple sclerosis (SPMS) in the phase 3 MAESTRO-01 trial. Dirucotide and placebo also did not differ significantly on any secondary end points in the trial.
The companies have announced that they are discontinuing ongoing clinical trials of dirucotide for the treatment of SPMS (including MAESTRO-02 and MAESTRO-03) and will review the available data before deciding on how to move forward.
No unexpected safety or tolerability issues were reported in the MAESTRO-01 trial.
FDA granted dirucotide fast-track status for the treatment of SPMS in September 2008.
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
